|
|
home > news |
 |
 |
INDUSTRY NEWS AND PRESS RELEASES |
 |
|
European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Approval marks the first all-oral, once-daily, fixed-duration Bruton’s
tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment
of CLL More>> |
|
|
SGS QUAY PHARMA RECEIVES QUEEN’S AWARD FOR INDUSTRY
Leading pharmaceutical contract development and manufacturing
organisation (CDMO) SGS Quay Pharma has received its Queen’s Award for
Enterprise. The award was presented by the Lord Lieutenant of Clwyd,
Henry Fetherstonhaugh, OBE, in a special ceremony at the company’s
global headquarters in Deeside Industrial Park, Flintshire. More>> |
|
|
+41 22 739 91 11
|
|
sgs.com/
|
|
1 Place des Alpes P.O. Box 2152 1211 Geneva 1 Switzerland
|
|
|
Signant Partners with Loftware for Adaptive Investigational Product Labeling
Collaboration reinforces Signant's end-to-end
clinical supplies management solutions and supports the complex
manufacturing and distribution models inherent in modern clinical
research More>> |
|
|
European Pharma Needs to Keep Manufacturing On The Continent And Become More Digitised To Stay Competitive, Say Speakers At New Event
The newly announced agenda for Connect in Pharma focuses on innovation
as the foundation of a strong pharmaceutical industry in Europe More>> |
|
|
Pioneering a New Era of Cell Therapy Manufacturing
Memphis facility becomes first North American CDMO to receive EMA approval for commercial allogeneic cell therapy production
Aug 09 2022: Following its successful inspection, our Memphis
cell therapy manufacturing facility is paving the way in the cell and
gene therapy industry as the first contract development and
manufacturing organization (CDMO) in North America to be awarded a
commercial GMP license to produce allogeneic cell therapy drug products
from the European Medicines Agency (EMA). More>> |
|
|
Sartorius to Acquire Albumedix, Strengthening its Portfolio of Innovative Advanced Therapy Solutions
Göttingen, August 8, 2022: The life science group Sartorius,
through its French listed subgroup Sartorius Stedim Biotech, has agreed
to acquire 100 percent of Albumedix Ltd. from private investors. The
Nottingham, UK-based company provides best-in-class recombinant
albumin-based solutions. Recombinant human albumin is an important
component for the biopharmaceutical industry required for various
applications, for example as an animal-free additive to cell culture
media and for the stabilization of vaccines and viral therapies. The
business, founded in 1984, has more than 100 employees and is expected
to generate revenue of approximately £33 million in 2022 with a
significant double-digit EBITDA margin. The agreed purchase price
amounts to approximately £415 million. The transaction is subject to
regulatory approval and is expected to close before the end of the third
quarter of 2022. More>> |
|
|
Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
09 Aug 2022, Darmstadt, Germany: Merck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a
full viral vector manufacturing offering including AAV, Lentiviral,
CDMO, CTO, and process development. This new platform enables
biopharmaceutical companies to increase the speed to clinical
manufacturing while reducing process development time and costs. More>> |
|
|
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
Cerevance to concurrently out-license one discovery-stage program
Boston, MA and Cambridge, UK – AUGUST 9, 2022: Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform. Cerevance will concurrently out-license one discovery-stage program to Merck as part of the collaboration. More>> |
|
|
Jackson ImmunoResearch Announces New Range of Antibodies for Serology and Diagnostics Market
West Grove, PA – 02 August 2022: Jackson ImmunoResearch, a
manufacturer of secondary antibodies and immunoreagents for the life
science market, announces a new addition to its range of products for
scientists developing immunoassays for the serology and diagnostics
markets. JIR Mouse Monoclonal Anti-Human IgE antibodies are the latest
addition to our suite of products suitable for diagnostics research and
development. More>> |
|
|
BioIVT Acquires Cypex, a Leading Manufacturer of Drug-Metabolizing Enzymes
Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
Westbury, NY – August 8, 2022 – BioIVT, a leading provider of
biospecimens, research models and services for drug and diagnostic
development, today announced that it has acquired Cypex, a renowned
manufacturer of recombinant xenobiotic metabolizing enzymes, based in
Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range
of proteins involved in drug metabolism. More>> |
|
|
|
 |
|
|
 |
News and Press Releases |
 |
PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform
WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 21, 2022--
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating
for a healthier world, today launched the GC 2400™ Platform, an
advanced, automated gas chromatography (GC), headspace sampler and
GC/mass spectrometry (GC/MS) solution designed to help lab teams
simplify lab operations, drive precise results, and perform more
flexible monitoring.
More info >> |
|
 |
White Papers |
 |
Clinical Trials in Emerging Markets: Goldmines or Landmines?
Pharm-Olam, LLC
Over the past decade, biopharmaceutical companies
have increasingly turned to emerging markets as a way
to reduce clinical trial costs and timelines. Areas such
as Eastern Europe, India, and Latin America—with their
ready population of treatment naïve patients—can be an
answer to the intense competition for patients seen in
developed markets. Many of the countries within these
regions may now be considered as “emerged” countries
but yet, conducting trials in these regions does require
some special attention and expertise. Before deciding to
conduct studies in these areas, companies should have a
full appreciation for the ethical, medical, regulatory, legal,
and operational hurdles that must be surmounted for
success. Here we highlight a number of those issues and
offer our recommendations for how sponsor companies
can deal with them effectively.
More info >> |
|
 |
Industry Events |
 |
Connect in Pharma
14-15 September 2022, Plaexpo, Geneva, Switzerland
The new event driving innovation for pharma and biopharma businesses,
Connect in Pharma will unite key players in Pharmaceutical and
Biopharmaceutical packaging and production in Geneva on 14 – 15
September 2022.
More info >> |
|
|